• search

Biocon wins bid for acquiring Nobex's assets

Written by: Staff
|

Bangalore, Mar 28 (UNI) India's leading biotechnology company, Biocon Limited, today announced that it has put up the winning bid for acquiring all the assets of Nobex Corporation, a drug development company which has filed for bankruptcy in December last.

Biocon and Nobex had earlier entered into an alliance for the global co-development and commercialisation of oral insulin and oral B-type natriuretic peptide (BNP), Biocon said in a release here.

Commenting on the acquisition, Biocon Chairperson and Managing Director Kiran Mazumdar-Shaw said ''this is truly a strategic acquisition which provides us with an immensely valuable IP platform.'' Nobex, which specialised in a proprietary drug delivery system to enable oral delivery of peptide drugs, had filed for bankruptcy on December one last. The auction was conducted on March 16 last and the Court approved the best bid by Biocon on March 20, the release said.

Biocon made an opening stalking horse bid of US dollars 3.5 million to acquire the assets of Nobex before the auction and emerged as the final bidder with a total commitment, including the settlement with the Creditors Committee, of US dollars five million and certain back-end royalties.

MORE UNI VK GD TS1650

For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more